Reader sentiment, not investment advice. One vote per visitor; click again to change it.
EWTX last changed hands at $40.30 (down 2.66%). At $4.38B, Edgewise Therapeutics is ranked #2209 by size among the 3132 stocks on BeStock.
The stock's 52-week band runs $14.25 to $48.51, and the latest print sits 16.9% under the top end of it.
8 analysts follow the stock and the average call is "buy". The mean target, $55.83, sits 38.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Trading closer to its 52-week high than most peers scores higher.
8 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
EWTX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $55.83, 38.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $41.20, so shares trade 2.2% below that estimate.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$40.30 is the latest print for EWTX, a move of -2.66% against yesterday's close of $41.40. Today's low and high so far: $39.98 and $41.79.
Equity value comes to $4.38B at the current price. By that measure it is number 2209 of the 3132 names in our coverage.
The year's floor is $14.25 and the ceiling $48.51. Shares are 16.9% away from that ceiling.
Our data shows no dividend paid by Edgewise Therapeutics over the trailing twelve months.
Of 8 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $55.83, with the most cautious at $51.00 and the most optimistic at $60.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on EWTX.